Etranacogene Dezaparvovec Significantly Improves Hemophilia B Past 2 Years

Phase 3 data presented at ASH 2023 show the gene therapy significantly reduced annualized bleeding rates and the number of total bleeds.

Related Keywords

United States ,San Diego ,California ,American , ,American Society Of Hematology ,American Society ,Hemophilia B ,Etranacogene Dezaparvovec ,Phase 3 ,Cash ,Mash 2023 ,Gene Therapy ,Etranadez ,Hemgenix ,